Description
An inhibitor of MAO-B (IC50 = ~0.1 μM); selective for MAO-B over MAO-A (IC50 = >10 μM); inhibits radioligand binding to sodium channel binding site 2, sigma-1, and sigma-2 receptors in rat brain membranes (IC50s = 8.2, 0.019, and 1.59 μM, respectively); inhibits high voltage-activated calcium currents and depolarization-induced tetrodotoxin-sensitive fast sodium currents in rat hippocampal neurons; inhibits veratrine-induced glutamate release in rat hippocampal slices (IC50 = 56 μM); inhibits maximal electroshock-induced tonic extension seizures in mice and rats (ED50s = 8 and 11.8 mg/kg, p.o.) as well as maximal seizures induced by bicuculline, picrotoxin, 3-mercaptopropionic acid, and strychnine in mice (ED50s = 26.9, 60.6, 21.5, and 104.1 mg/kg, p.o., respectively)
Formal name: 2S-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino]-propanamide, monomethanesulfonate
Synonyms: EMD 1195686|FCE 26743|NW-1015|PNU-151774E
Molecular weight: 398.4
CAS: 202825-46-5
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Ion Channel Modulation|Blockers||Product Type|Biochemicals|Small Molecule Inhibitors||Research Area|Neuroscience|Neurodegenerative Disorders|Parkinson’s Disease||Research Area|Neuroscience|Seizure Disorders